Edaravone: A new drug approved for ALS

Jeffrey D Rothstein

doi:10.1016/j.cell.2017.10.011

Edaravone: A new drug approved for ALS

Cell. 2017 Nov 2;171(4):725. doi: 10.1016/j.cell.2017.10.011.

Author

Jeffrey D Rothstein¹

Affiliation

¹ Brain Science Institute and Dept of Neurology, Johns Hopkins University, Baltimore, MD 21218, USA. Electronic address: jrothstein@jhmi.edu.

PMID: 29100067
DOI: 10.1016/j.cell.2017.10.011

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.

MeSH terms

Amyotrophic Lateral Sclerosis / drug therapy*
Antipyrine / analogs & derivatives*
Antipyrine / therapeutic use
Drug Approval*
Edaravone
Excitatory Amino Acid Antagonists / therapeutic use*
Humans
Riluzole / therapeutic use

Substances

Excitatory Amino Acid Antagonists
Riluzole
Edaravone
Antipyrine